A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer

Armstrong, 2006, Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N. Engl. J. Med., 354, 34, 10.1056/NEJMoa052985 McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101 Piccart, 2000, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J. Natl. Cancer Inst., 92, 699, 10.1093/jnci/92.9.699 Fisher, 1986, Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial, J. Clin. Oncol., 4, 459, 10.1200/JCO.1986.4.4.459 Untch, 2008, Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial, Ann. Oncol., 19, 1090, 10.1093/annonc/mdn005 Geyer, 2006, Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N. Engl. J. Med., 355, 2733, 10.1056/NEJMoa064320 Fiorica, 2004, Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study, Gynecol. Oncol., 92, 10, 10.1016/j.ygyno.2003.11.008 Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N. Engl. J. Med., 347, 472, 10.1056/NEJMoa020461 Markman, 1996, Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report, Gynecol. Oncol., 62, 4, 10.1006/gyno.1996.0181 Bookman, 2003, Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group, J. Clin. Oncol., 21, 283, 10.1200/JCO.2003.10.104 Alberts, 2007, Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211), Int. J. Gynecol. Cancer, 17, 784, 10.1111/j.1525-1438.2007.00882.x Burger, 2007, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study, J. Clin. Oncol., 25, 5165, 10.1200/JCO.2007.11.5345 Smyth, 2007, Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients, Clin. Cancer Res., 13, 3617, 10.1158/1078-0432.CCR-06-2878 Walker, 2007, Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer, Gynecol. Oncol., 106, 461, 10.1016/j.ygyno.2007.05.009 O'Donnell, 2005, Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen, Endocr. Relat. Cancer, 12, 851, 10.1677/erc.1.01039 Zhou, 2008, Hormone replacement therapy and ovarian cancer risk: a meta-analysis, Gynecol. Oncol., 108, 641, 10.1016/j.ygyno.2007.12.003 Silva, 1998, Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation, Gynecol. Oncol., 71, 240, 10.1006/gyno.1998.5153 Thürlimann, 2005, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, N. Engl. J. Med., 353, 2747, 10.1056/NEJMoa052258 Stanway, 2006, Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor, Clin. Cancer Res., 12, 1585, 10.1158/1078-0432.CCR-05-1996 Chia, 2008, Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT, J. Clin. Oncol., 26, 1664, 10.1200/JCO.2007.13.5822 Neven, 2008, Fulvestrant (Faslodextrade mark) in advanced breast cancer: clinical experience from a Belgian cooperative study, Breast Cancer Res. Treat., 109, 59, 10.1007/s10549-007-9628-2 Wakeling, 1991, A potent pure antiestrogen with clinical potential, Cancer Res., 51, 3867 Robertson, 2003, Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer, Cancer Chemother. Pharmacol., 52, 346, 10.1007/s00280-003-0643-7 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J. Natl. Cancer Inst., 92, 205, 10.1093/jnci/92.3.205 Guppy, 2002, CA125 response: can it replace the traditional response criteria in ovarian cancer?, The Oncologist, 7, 437, 10.1634/theoncologist.7-5-437 Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control. Clin. Trials, 10, 1, 10.1016/0197-2456(89)90015-9 Mlineritsch, 2007, Fulvestrant (‘Faslodex’) in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme, Breast Cancer Res. Treat., 106, 105, 10.1007/s10549-006-9482-7 Sasano, 2008, Intracrinology of estrogens and androgens in breast carcinoma, J. Steroid Biochem. Mol. Biol., 108, 181, 10.1016/j.jsbmb.2007.09.012 du, 2002, Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer, Ann. Oncol., 13, 251, 10.1093/annonc/mdf038 Duffaud, 2001, D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group study, Anticancer Drugs, 12, 159, 10.1097/00001813-200102000-00010 Chura, JC, Ryu, HS, Simard, M, Poirrer, D, Tremblay, Y, Brooker, DC, Blomquist, CH, Argenta PA Steroid-converting enzymes in human ovarian cancers. Mol Cell Endocrinol. In press. Chura, JC, Blomquist, CH, Ryu, HS, Argenta PA. estrone sulfatase activity in patients with advanced ovarian cancer. Gynecol Oncol 2009;112(1)(Jan):205–9. García-Velasco, 2008, Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma, Clin. Transl. Oncol., 10, 367, 10.1007/s12094-008-0213-x Høgdall, 2007, Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the ‘MALOVA’ ovarian cancer study, Oncol. Rep., 18, 1051 Neven, 2008, Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study, Breast Cancer Res. Treat., 109, 59, 10.1007/s10549-007-9628-2 Osborne, 2002, Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial, J. Clin. Oncol., 20, 3386, 10.1200/JCO.2002.10.058